Newark, DE, United States of America

Ganfeng Cao

This inventor holds 32 USPTO granted patents and 8 published patent applications, plus 7 CIPO patents and 14 EPO patents. Top assignees: Incyte Corporation, Incyte Holdings Corporation, Pfizer Corporation. Active years: 2007-2025.

USPTO Granted Patents = 32 

% Patents Active = 81.3

 

 

Average Co-Inventor Count = 5.5

ph-index = 8

Forward Citations = 314(Granted Patents)


Location History:

  • Bear, DE (US) (2008 - 2012)
  • Wilmington, DE (US) (2014)
  • Newark, DE (US) (2007 - 2017)
  • Chadds Ford, PA (US) (2018 - 2024)

Company Filing History:


Years Active: 2007-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Protein Arginine Methyltransferase 5
JAK Inhibitors
Pim Kinase Inhibitor
LSD1 Inhibitor
Chemokine Receptor Antagonists
Purinone Derivatives
HM74A Agonists
3-Aminopyrrolidine Derivatives
3-Aminocyclopentanecarboxamides
Piperazinylpiperidine Derivatives
Bipyrazole Derivatives
32 patents (USPTO):Explore Patents

Title: Ganfeng Cao: Pioneering Inventor from Newark, DE

Introduction: Ganfeng Cao is a distinguished inventor based in Newark, DE, known for his groundbreaking contributions to various technological fields.

Latest Patents: Ganfeng Cao holds several patents in the areas of renewable energy, artificial intelligence, and biotechnology, showcasing his versatility and innovative spirit.

Career Highlights: With a career spanning over two decades, Ganfeng Cao has worked with leading research institutions and companies, consistently pushing the boundaries of innovation.

Collaborations: Throughout his career, Ganfeng Cao has collaborated with top scientists, engineers, and inventors globally, fostering a culture of creativity and excellence in his projects.

Conclusion: Ganfeng Cao's relentless pursuit of innovation and his remarkable contributions have solidified his position as a trailblazing inventor in the technological landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…